As severe (grade3) gland atrophy, scanty lacy colloid, cell desquamation, vacuolization and inflammation were significantly the highest in group III (GLP group) (75%,62.5%,50%,75%) compared to (0%) in other groups (I, II, IV) respectively, also focal adenomatous changes were significantly higher in group III (GLP group) (62.5%) compared to (0%) in groups (I, and II) and (12.5%) in group (IV) respectively ( p = 0.037414, 0.037414,0.0027, 0.0455 & 0.038867, respectively) (Table 6
This systemic anti-inflammatory effect is one reason why researchers often report improvements in seemingly unrelated symptoms when using the peptide for a specific indication, experiencing reduced joint pain while treating a gut issue, for example, or improved recovery times while treating a specific injury
This makes it the first triple-agonist peptide to reach advanced clinical development
C., & Church, M
You can also get home delivery by placing an order online